EMA Guide On Trial Master Files To Help Compliance With Upcoming CT Regulation
The European Medicines Agency has issued a new draft guideline to clarify its regulatory expectations relating to the maintenance of clinical trial master files in line with the upcoming EU Clinical Trials Regulation.
You may also be interested in...
The number of deficiencies found by EU GCP inspectors rose to 1,033 in 2016, compared with 912 in 2015, although the number of problematic findings considered “critical” was down slightly. Meanwhile, Japan has asked to join the EMA/FDA initiative on GCP inspections.
The European Medicines Agency is inviting feedback on a draft reflection paper that explains how companies can comply with good clinical practice (GCP) requirements in relation to trial master files, whether these are maintained in paper or electronic formats1.
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.